Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
December 8, 2025BloodOpen Access

Itacitinib in combination with post-transplant cyclophosphamide and tacrolimus (ICT) as GVHD prophylaxis for reduced intensity matched donor peripheral blood stem cell hematopoietic cell transplantation: Interim analysis

View Full Paper
Ask AI
Bookmark
Share

Authors

DYDongyun YangRIRhiannon ImbeahBBBrian Ball

Discussion

Loading...

Member takes

Overview

Pilot study shows itacitinib combined with tacrolimus reduces acute graft-versus-host disease in hematopoietic cell transplantation, suggesting enhanced safety.

Key Points

  • To evaluate the safety of itacitinib added to post-transplant cyclophosphamide-based GVHD prophylaxis.
  • Single-center pilot study with 20 patients undergoing matched donor PBSC HCT.
  • Patients received PTCy and tacrolimus with itacitinib for GVHD prophylaxis.
  • Cohorts were evaluated for 60 or 90 days of tacrolimus administration.
  • All patients achieved engraftment with median time to neutrophil engraftment of 16 days.
  • One-year overall survival was 88% and relapse-free survival was 85%.
  • Cumulative incidence of grade 2-4 acute GVHD was 10% and chronic GVHD was 6%.

Cite This Study

Yang et al. (2025) studied this question.

synapsesocial.com/papers/69362f714fa91c937236e201https://doi.org/10.1182/blood-2025-2455
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Reduced dose post-transplant cytoxan (Intermediate -Dose) in combination with abatacept after matched unrelated donor transplant for high -risk hematological malignancy may reduce treatment related mortality and risk of relapse.2025
  2. 2An open-label phase I study of JAK inhibitor ruxolitinib with and without CTLA-4 ig abatacept for the prophylaxis of graft-versus-host ddsease and cytokine release syndrome after T-cell replete haploidentical peripheral blood hematopoietic cell transplantation2025
  3. 3Phase II Study of post transplant cyclophosphamide-based graft versus host disease prophylaxis after HLA-mismatched unrelated donor transplantation and reduced intensity conditioning: Results from the NMDP-sponsored access expansion Study2025
  4. 4JAK2/mTOR Inhibition Fails to Prevent Acute GVHD Despite Reduced Th1/Th17 cells: Final Phase II Trial Results2024 · 3 citations
  5. 5Post-transplant cyclophosphamide-based graft-verses-host disease (GVHD) prophylaxis is associated with a low incidence of fibrotic chronic GVHD after allogeneic hematopoietic cell transplantation across diverse donor types2025